文章摘要

文章信息/Info

Title:: -

作者:: 桑震池; 陈书艳; 上海交通大学医学院附属新华医院心内科,上海 200092

Author(s):: -

关键词:: 他汀类药物; 烟酸; 抗氧化剂

Keywords:: -

分类号:: R972.6

DOI:: -

文献标识码:: A

摘要:: 冠心病与血脂异常以及脂蛋白的氧化的关系已经逐渐明确，而调脂和抗氧化治疗在冠心病一级和二级预防中的作用也越来越明确，本文分别从他汀类药物、烟酸、抗氧化剂的作用机制、临床效果方面进行阐述，同时对联合降脂药物治疗的临床结果进行分析。

Abstract:: -

参考文献/References

［1］ Davignon J. Beneficial cardiovascular pleiotropic effects of statins［J］. Circulation, 2004, 109(23 Suppl 1); Ⅲ39-Ⅲ43.

［2］ Ridker PM, Cannon CP, Morrow D, et al. Creactive protein levels and outcomes after statin therapy［J］. N Engl J Med, 2005, 352(1):20-28.

［3］汪俊元，王安才. 他汀类药物对血管重构的干预机制［J］. 心脏杂志， 2006， 18（3）：356-358.

［4］付文波，丁世芳.他汀类药物对高血压病心血管重建作用的研究现状［J］. 心脏杂志， 2006， 18（5）：588-590.

［5］ Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes［J］. N Engl J Med, 2004, 350(15):1495-1504.

［6］ Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial［J］. Am J Cardiol, 2005, 96(5A):61F-68F.

［7］ Nissen SE，Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial［J］. JAMA, 2004, 291(9):1071-1080.

［8］殷忠，刘丽文，李兰荪，等. 长期应用阿托伐他汀对冠心病患者颈动脉粥样斑块的影响［J］. 心脏杂志, 2007, 19(3):311-314.

［9］ Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, highdensity lipoprotein cholesterol, and regression of coronary atherosclerosis［J］. JAMA, 2007, 297(5):499-508.

［10］Ganji SH, Qin S, Liu Y, et al. Niacin inhibits LDL oxidation and redoxsensitive VCAM1 and MCP1 expression in human aortic endothelial cells ［abstract］［J］. Arterioscler Thromb Vasc Biol, 2004, 24:E-125.

［11］杜海科,王世鑫,刘彦,等. 烟酸对染矽尘大鼠一氧化氮合酶表达的影响［J］. 中华预防医学杂志， 2004, 38(3):186-189.

［12］Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells［J］. J Lipid Res, 2004, 45(10):1835-1845.

［13］Pike NB, Wise A. Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipidlowering drug?［J］. Curr Opin Investig Drugs, 2004, 5(3):271-275.

［14］Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATPbinding cassette A1 in monocytoid cells by niacin［J］. Biochem Pharmacol, 2004, 67(3):411- 419.

［15］Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low highdensity lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study)［J］. Am J Cardiol, 2004, 93(3):307-312.

［16］Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST)［J］. Am J Cardiol, 1994, 74(9):875-883.

我们的网站为什么显示成这样？

他汀类药物、烟酸、抗氧化剂对降脂和冠状动脉粥样硬化的作用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics